Survival for somatostatinoma

Somatostatinoma is a type of neuroendocrine tumour (NET) that usually starts in the pancreas or small bowel. Survival for somatostatinomas depends on many factors. So no one can tell you exactly how long you will live.

Doctors usually work out the outlook for a certain disease by looking at large groups of people. Because somatostatinomas are rare cancers, the survival of this disease is harder to estimate than for other, more common cancers.

These are general statistics based on small groups of people. Remember, they can’t tell you what will happen in your individual case. Your doctor can give you more information about your own outlook (prognosis).

You can also talk about this with the Cancer Research UK nurses on freephone 0808 800 4040, from 9am to 5pm, Monday to Friday.

What affects survival

Survival depends on many factors. It depends on the stage and grade of the tumour when it was diagnosed. The stage describes the size of the tumour and whether it has spread. The grade means how abnormal the cells look under a microscope.

Another factor is how well you are overall. 

Survival for somatostatinomas

There are no UK survival statistics for all the different types of NETs. The statistics below come from an international study. Please be aware that due to differences in health care systems, data collection and the population, these figures may not be a true picture of survival in the UK.

Most people with a somatostatinoma that hasn't spread to other parts of the body have surgery to try to cure their cancer.

Almost 80 out of every 100 people (almost 80%) survive somatostatinomas for 5 years or more after having surgery to try to cure their cancer.

Survival for NETs of the pancreas

In the UK, no statistics are available for the survival of all the different types of pancreatic NETs. This is because researchers haven’t collected this information yet. The information we have here is the 1 year survival for all types of pancreatic NETs.

This information is from people diagnosed in England between 2013-2015. Because this is for England only, it might not be the same for the whole of the UK.

Around 80 out of every 100 people (80%) diagnosed with a pancreatic NET survive for 1 year or more. 

About these statistics

The term 1 year, 5 year and 10 year survival does not mean that you will only live for 1, 5 or 10 years. They relate to the number of people who are still alive 1 year, 5 years or 10 years after their diagnosis.

Some people live much longer than 10 years.

What next?

You might want to read our information about treatment for somatostatinomas. 

Last reviewed: 
12 Jun 2019
  • Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival 
    T Halfdanarson and others
    Annals of Oncology, 2008. Vol 19, Pages 1727-1733

  • 1-Year survival rates for neuroendocrine tumour patients in England
    T Genus and others
    Public Health England, 2017

  • Somatostatinoma syndrome
    P Economopoulos and C Christopoulos
    Annals of Gastroenterology, 2001. Vol 14, Issue 4, Pages 252-260

  • Rare functioning pancreatic endocrine tumors
    D O'Toole and others
    Neuroendocrinology, 2006. Vol 84, Pages 189-195

  • ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes 
    R T Jensen and others
    Neuroendocrinology, 2012. Vol 95, Pages 98-119 

Related links